(VIANEWS) – Primoris Services Corporation (PRIM), Corcept Therapeutics Incorporated (CORT), Erie Indemnity Company (ERIE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Primoris Services Corporation (PRIM)
29.5% sales growth and 11.48% return on equity
Primoris Services Corporation, a specialty contractor company, provides a range of construction, fabrication, maintenance, replacement, and engineering services in the United States and Canada. It operates through three segments: Utilities, Energy/Renewables, and Pipeline Services. The Utilities segment offers installation and maintenance services for new and existing natural gas distribution systems, electric utility distribution and transmission systems, and communications systems. The Energy/Renewables segment provides a range of services, including engineering, procurement, and construction, as well as retrofits, highway and bridge construction, demolition, site work, soil stabilization, mass excavation, flood control, upgrades, repairs, outages, and maintenance services to renewable energy and energy storage, renewable fuels, petroleum, refining, and petrochemical industries, as well as state departments of transportation. The Pipeline Services segment offers a range of services comprising pipeline construction, maintenance, facility, and integrity services; installation of compressor and pump stations; and metering facilities for entities in the petroleum and petrochemical industries, as well as gas, water, and sewer utilities. The company was founded in 1960 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Primoris Services Corporation has a trailing twelve months EPS of $2.4.
PE Ratio
Primoris Services Corporation has a trailing twelve months price to earnings ratio of 13.89. Meaning, the purchaser of the share is investing $13.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.48%.
2. Corcept Therapeutics Incorporated (CORT)
22.3% sales growth and 19.55% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.8.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 40.95. Meaning, the purchaser of the share is investing $40.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 21.5%, now sitting on 450.03M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 78.6% and 71.4%, respectively.
Moving Average
Corcept Therapeutics Incorporated’s value is way higher than its 50-day moving average of $27.18 and way higher than its 200-day moving average of $25.95.
3. Erie Indemnity Company (ERIE)
11% sales growth and 26.99% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $7.65.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 43.5. Meaning, the purchaser of the share is investing $43.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.99%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Erie Indemnity Company’s EBITDA is 5.42.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 61.6% and 38.8%, respectively.
Volume
Today’s last reported volume for Erie Indemnity Company is 79920 which is 28.66% below its average volume of 112028.
4. MYR Group (MYRG)
7.2% sales growth and 15.76% return on equity
MYR Group Inc., through its subsidiaries, provides electrical construction services in the United States and Canada. It operates through two segments, Transmission and Distribution, and Commercial and Industrial. The company's Transmission and Distribution segment offers a range of services on electric transmission and distribution networks, and substation facilities, including design, engineering, procurement, construction, upgrade, maintenance, and repair services with primary focus on construction, maintenance, and repair to customers in the electric utility industry. Its services include construction and maintenance of high voltage transmission lines, substations, and lower voltage underground and overhead distribution systems, and renewable power facilities; and limited gas construction services, as well as emergency restoration services in response to hurricane, ice, or other storm related damages. This segment serves as a prime contractor to customers, such as investor-owned utilities, cooperatives, private developers, government-funded utilities, independent power producers, independent transmission companies, industrial facility owners, and other contractors. Its Commercial and Industrial segment provides services, such as design, installation, maintenance, and repair of commercial and industrial wiring; and installation of traffic networks, bridge, roadway, and tunnel lighting. This segment offers its services for airports, hospitals, data centers, hotels, stadiums, convention centers, renewable energy projects, manufacturing plants, processing facilities, waste-water treatment facilities, mining facilities, and transportation control and management systems. It serves general contractors, commercial and industrial facility owners, governmental agencies, and developers. MYR Group Inc. was founded in 1891 and is headquartered in Henderson, Colorado.
Earnings Per Share
As for profitability, MYR Group has a trailing twelve months EPS of $5.44.
PE Ratio
MYR Group has a trailing twelve months price to earnings ratio of 26.59. Meaning, the purchaser of the share is investing $26.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.76%.
5. Edwards Lifesciences (EW)
7.1% sales growth and 22.06% return on equity
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Edwards Lifesciences has a trailing twelve months EPS of $2.34.
PE Ratio
Edwards Lifesciences has a trailing twelve months price to earnings ratio of 32.59. Meaning, the purchaser of the share is investing $32.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.06%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Edwards Lifesciences’s EBITDA is 7.7.
Volume
Today’s last reported volume for Edwards Lifesciences is 646691 which is 86.46% below its average volume of 4778520.
Sales Growth
Edwards Lifesciences’s sales growth is 10.9% for the current quarter and 7.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 5.82B for the twelve trailing months.
6. Visteon Corporation (VC)
6.3% sales growth and 23.03% return on equity
Visteon Corporation engineers, designs, and manufactures cockpit electronics and connected car solutions for vehicle manufacturers worldwide. The company provides instrument clusters, including standard analog gauge clusters to high-resolution, all-digital, fully reconfigurable, 2-D, and 3-D display-based devices; information displays that integrate a range of user interface technologies and graphics management capabilities; and audio and infotainment systems that allows vehicle occupants to connect their mobile devices to the system and safely access phone functions, listen to music, stream media, and enable mobile connectivity applications. It also offers infotainment solutions, including Phoenix display audio and embedded infotainment platform; telematics control unit to enable secure connected car services, software updates, and data; SmartCore, an automotive-grade, integrated domain controller to enhance efficiency, and reduce power consumption and cost; and head-up displays (HUD), such as combiner HUD and windshield HUD that present critical information to the driver. Visteon Corporation was founded in 2000 and is headquartered in Van Buren, Michigan.
Earnings Per Share
As for profitability, Visteon Corporation has a trailing twelve months EPS of $5.39.
PE Ratio
Visteon Corporation has a trailing twelve months price to earnings ratio of 23.75. Meaning, the purchaser of the share is investing $23.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.03%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 55.3% and 48%, respectively.
Volume
Today’s last reported volume for Visteon Corporation is 864906 which is 172.19% above its average volume of 317753.
